Renibus Therapeutics
Southlake, United States · Biopharma, Biotechnology, Healthcare
Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic su
Key facts
- Headquarters
- Southlake, United States
- Employees
- 332
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Private
- Website
- renibus.com
- Company page
Recent activity at Renibus Therapeutics
- : Renibus Therapeutics
- : Renibus Therapeutics
- : Renibus Therapeutics Announces Final Close Of Upsized Series B Financing, Bringing Total Round To $72 Million
- : Renibus Therapeutics Announces $47 Million Financing To Advance Lead Program Rbt-1 Through Pivotal Phase 3 Trial
- : Renibus Therapeutics
- : Renibus Therapeutics Raises $33 Million Bridge Financing To Advance Its Portfolio Of Cardiorenal Product Candidates
- : Renibus Therapeutics, Inc
- : Renibus Therapeutics, Inc
- : Renibus Therapeutics, Inc.
- : Renibus Therapeutics, Inc.
Renibus Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Venture | $110.9M |
| Sep 2023 | Venture | $95.9M |
| Sep 2023 | Series B | Undisclosed |
| Jul 2023 | Funding Round | $47.0M |
| Jun 2023 | Venture | $63.8M |
Leadership
- Jeff Keyser, Co-Founder, President and COO
- Alvaro Guillem, Director
- D. Keyser, Executive Officer, Director
- Henrik Rasmussen, Director
- Bhupinder Singh, Director
- Frank Stonebanks, Executive Officer, Director
- Alvaro Guillem, Executive Officer, Director
- D. Keyser, Executive Officer, Director
- Henrik Rasmussen, Director
- Bhupinder Singh, Director
- Bhupinder Singh, Director
- Henrik Rasmussen, Director
Verified email and direct lines for Renibus Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Renibus Therapeutics in the news
- Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase - PR Newswire (Sep 24, 2026)
- Renibus Therapeutics Announces Oral Presentation on Phase 3 PROTECT Trial Data for RBT-1 at the American Association for Thoracic Surgery (AATS) Annual Meeting - PR Newswire (Apr 30, 2026)
- Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk - Clinical Trials Arena (Apr 25, 2025)
- Renibus’ cardiac surgery drug aces phase 2 trial as biotech adds extra CEO - Fierce Biotech (Jan 05, 2023)
- FDA Grants Orphan Drug Designation to Veverimer for Anti-GBM Disease - DocWireNews (Jun 13, 2025)
- Leadership Transition at Renibus Therapeutics: Co-Founder Appointed as Sole CEO - Dallas Innovates (Mar 22, 2024)
- Southlake biopharmaceutical company raises $47M in Series B financing - Fort Worth Report (Jul 19, 2023)
- Southlake's Renibus Therapeutics raises $47 million to advance novel drug to Phase 3 trial - Dallas News (Jul 18, 2023)
Companies similar to Renibus Therapeutics
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Wave Life Sciences · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- HARMONY BIOSCIENCES · Biopharma, Biotechnology, Health Care, Medical, Therapeutics
About Renibus Therapeutics: questions and answers
What does Renibus Therapeutics do?
Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic su
Where is Renibus Therapeutics headquartered?
Renibus Therapeutics is headquartered in Southlake, United States.
How many employees does Renibus Therapeutics have?
Renibus Therapeutics has about 332 employees.
Has Renibus Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Renibus Therapeutics. The most recent, $110.9M, was in Jul 2025.
Who leads Renibus Therapeutics?
Jeff Keyser is a Co-Founder, President and COO at Renibus Therapeutics.
What is the latest news on Renibus Therapeutics?
On Jul 17, 2025, Renibus Therapeutics
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy